$RLFTF DD (opinion) by IN on Ya-h00: Apparently, not

New Post Public Reply Private Reply Replies (0) Message Board
mc67
296
$RLFTF DD (opinion) by IN on Ya-h00: Apparently, not everyone here is blessed with the ability to read a PR. Let me dissect it for those people again:
* "Zyesami Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival" => You don't claim that if it's not true, or you want to end up in court/jail

* "Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013)" => That means ALL 196 patients from all 10 hospitals taken together were evaluated according to the pre-determined primary endpoint metrics. This analysis has shown improved recovery from respiratory failure (definition of respiratory failure per the FDA) both at day 28 and day 60. This has no value like "number of days" or so attached because "recovery" is a binary event. But whatever the difference is, the P values tell us that it is very unlikely due to chance. Much better than the "gold standard" of P < 0.05.

* "also demonstrated a meaningful benefit in survival (P under .001) after controlling for ventilation status and treatment site" => Let's get to the controlling part. That means that you normalize your data in a way where you try to eliminate external factors, so that the results really reflect the effect of the drug you're studying. ALL patients get the adjustment applied, placebo or treatment alike. Adjustments need to be scientifically valid and usually are agreed with the FDA. Severity is one of those external factors that are expressly encouraged to be controlled for in FDA guidance. Adjusting for ventilator status (HFNC, positive pressure, ventilator) IS adjusting for severity. Adjusting for treatment sites (tertiary vs. regional), when some are over 200 % ICU capacity, seems like a very valid external factor not intrinsic to how the drug works as well. The adjustment is for the mortality evaluation ONLY. All said and done, the treatment arm did better than placebo AND that fact is less likely to be down to chance than 1 in 1000 (P under 0.001)!

* "In addition to the robust overall significance across all 196 treated patients at all 10 clinical sites, the prespecified analysis of recovery from respiratory failure is clinically and statistically significant in the 127 patients treated by High Flow Nasal Cannula (HFNC) (P = .02), compared to those treated with mechanical or non-invasive ventilation at tertiary care hospitals." => IN ADDITION to ALL PATIENTS mentioned above, we'll now get more detailed data on a subgroup. Those patients previously mentioned in the 28 day interim readout. Those that haven't progressed to a ventilator (which nobody will hopefully have to do once Zyesami is in hospitals), those which were treated at hospitals that had enough capacity around and at least a specialist on call at all times. Basically the most meaningful patient group to really show what's going on with this drug biologically in a patient.

* "In this group, ZYESAMI™ patients had a 71% chance of successful recovery by day 28 vs. 48% in the placebo group (P = .017) and a 75% rate of successful recovery by day 60 vs. 55% in the placebo group (P = .036). => In other words, that's a clinically meaningful improvement in getting off assisted breathing, which is very unlikely to be down to chance. So the drug works.

* "Eighty-four percent (84%) of HFNC patients treated at tertiary medical centers with ZYESAMI™ survived to day 60 compared with 60% of those treated with placebo (P = .007)." => Yes, the tertiary centers do a good job now keeping patients alive. Much more than the 20-30 % rates being circulated on the $CYDY board for example. But with Zyesami and good care, when you go to a hospital with critical COVID, you have an 84 % chance of surviving that now for at least 60 days! That's bigly. COVID will be a flu soon (especially when we get the inhalers out).

* "To the company's knowledge, ZYESAMI™ is the first COVID-19 therapeutic to demonstrate advantages in both survival and recovery from critical COVID-19 in a randomized, double-blind multicenter trial." => We're the first. The one. The only.

* "On the basis of these findings, NeuroRx plans to apply immediately to the United States Food and Drug Administration ("FDA" for Emergency Use Authorization (EUA) and to subsequently submit a New Drug Application (NDA)." => As stated in the conference call, we have the data we need IN HAND to apply NOW for EUA. Dr. Javitt is no amateur with the FDA. And, he even thinks this RCT will serve as the basis for a New Drug Approval, because ALL ENDPOINTS WERE MET! This was a blazing success!

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 154

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 71

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 154

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 27

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 129

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Maryland Handgun Ban Suit Puts Ruger in Legal Crossfire

Updated Category News Views 150

A January Deadline With Real Commercial Teeth Maryland has turned a trigger-design dispute into a fresh legal and retail headache, and the clock is not polite about it. The National Shooting Sports Foundation filed suit against the state over S.B. 334, which is scheduled to take effect Jan. 1, 2027. The law bars sales of certain pistols with cruciform trigger bars,...

Continue Reading

Top 5 Most Recently Viewed Articles

Avaline's Organic Wines Shine in New Holiday Campaign

Updated Category News Views 250

Avaline Unveils Its Charming Holiday Campaign The organic wine brand Avaline is excited to kick off its holiday campaign, which beautifully captures the spirit of the season. By blending nostalgia with festive cheer, Avaline invites everyone to relish the little moments that make the holidays special. The campaign draws inspiration from beloved holiday films, reminding us...

Continue Reading
Exploring In-Game Advertising: Key Insights for Brands

Updated Category News Views 206

Unlocking the Potential of In-Game Advertising Recent research conducted by Cint sheds light on the rising value of in-game advertising (IGA) for brands and the necessity for measurement standards within this dynamic marketing field. Video games have increasingly become a vital platform for advertisers, offering rich engagement opportunities. Consumers are showing...

Continue Reading
Mawson Infrastructure Reports Significant Operational Growth

Updated Category News Views 66

Update on Mawson Infrastructure Group's Operations Mawson Infrastructure Group Inc. recently released a significant operational update that highlights impressive growth in its digital colocation sector. The figures show a remarkable 166% increase in digital colocation revenue compared to a year ago, specifically in August 2023, and a solid 25% growth from the previous...

Continue Reading
Cybersecurity Landscape Evolves: New Threats and Insights

Updated Category News Views 292

An Overview of Current Cybersecurity Threats The digital landscape is becoming increasingly complex, and organizations are challenged with new and emerging cybersecurity threats. Red Canary's recent report dives deep into these threats, highlighting alarming trends that security teams must address now. The Rise of Identity Attacks As technology continues to advance, so do...

Continue Reading
US Family Health Plan Brighton Marine Celebrates Recognition with Awards

Updated Category News Views 188

US Family Health Plan Brighton Marine Honored with Excellence Awards Recent accolades reflect the dedication and quality of care provided by US Family Health Plan Brighton Marine. This esteemed organization has been awarded three Human Experience Pinnacle of Excellence Awards, recognizing it as one of the top health plans across the nation. Such recognition highlights the...

Continue Reading